Zafgen, Inc. (ZFGN)
(Delayed Data from NSDQ)
$2.65 USD
+0.09 (3.52%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.65 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Larimar Therapeutics, Inc. [ZFGN]
Reports for Purchase
Showing records 1 - 20 ( 45 total )
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
Dropping Coverage Due to Realignment of Analyst Resources
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
Potential Reverse Merger with Chondrial Therapeutics
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
A Chapter Closes for ZGN-1061; Downgrade to Neutral
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
Downgrading to NEUTRAL Due to Unclear ZGN-1061/T2D Development Timelines
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
Healthcare - Earnings Recap: The More Analysis, The Merrier, Especially When Data-Driven
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
2Q19 - Let''s Revisit the Guidelines on FDA Clinical Holds
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
Alignment with FDA on Nonclinical Study; Data by YE
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L